Disclosure of Patents a. Member shall notify PRIA board if member knows or reasonably should know of patent holdings and applications of member organization that may likely be infringed by the implementation of a PRIA standard work product adopted or under development. Members shall not file patent applications based on improvements or refinements to subject matter considered for inclusion in a PRIA standard work product.
Disclosure of Patents. APPLICATIONS TO ALS. Within thirty (30) days following the Effective Date, Abbott shall, to the extent not previously disclosed, disclose to ALS the complete text of, and all other information in its possession or control directly related to (a) all patent applications included in the Patents filed anywhere in the Territory; and (b) all patents included in the Patents as well as all information in Xxxxxx'x, its Affiliates and its patent counsel's possession concerning the institution or possible institution of any interference, opposition, reexamination, reissue, revocation, nullification or any official proceeding involving an issued patent included in the Patents anywhere in the Territory. ABBOTT MAKES NO WARRANTIES AND SPECIFICALLY DISCLAIMS ANY WARRANTIES REGARDING THE PATENTABILITY OF PENDING PATENT APPLICATIONS.
Disclosure of Patents. Within 30 days of the Effective Date, Nycomed will disclose to POZEN the complete text of all pending patent applications included in the Licensed Technology as well as copies of all correspondence concerning the prosecution thereof made or received by or on behalf of Nycomed to or from patent offices and any information or correspondence received by or on behalf of Nycomed from patent offices concerning the institution of any interference, opposition, re-examination, reissue, revocation, nullification or any official proceeding involving any Licensed Patents included in the Licensed Technology. Nycomed will ship such materials DDU (ICC Incoterms 2000) to a place of destination to be named by POZEN within 10 days after the Effective Date.
Disclosure of Patents. 4.1 During the IPR REVIEW PERIOD, each PARTICIPANT shall disclose to the MANAGEMENT BOARD, in writing, the existence of its NECESSARY CLAIMS that it has determined cover a DRAFT SPECIFICATION and OTHER OUTPUT that are personally known to the individuals acting on behalf of such PARTICIPANT with respect to the DRAFT SPECIFICATION and OTHER OUTPUT, provided that it is understood and agreed that such individuals do not represent that they personally know of all potentially pertinent claims of patents and patent applications owned or claimed by the PARTICIPANT they represent or any third parties.
4.2 The obligation set forth in Section 4.1 above does not, however, imply any obligations on PARTICIPANTS (collectively or individually) to perform or conduct patent searches. Further, nothing in this Agreement nor the act of a PARTICIPANT submitting, supporting, or approving a proposal for a SPECIFICATION and OTHER OUTPUT shall be construed or otherwise interpreted as any kind of express or implied representation that such PARTICIPANT does or does not hold any patents or patent applications which contain claims that cover such SPECIFICATION and OTHER OUTPUT.
Disclosure of Patents. Section 4.9.1 of the Disclosure Schedule lists all of the Patents owned by the Company or any Company Subsidiary included within the Aeroquin™ IP, setting forth in each case the jurisdictions in which Issued Patents have been issued and Patent Applications have been filed. Section 4.9.1 of the Disclosure Schedule lists all of the Patents within the Aeroquin™ IP in which the Company or any Company Subsidiary has any right, title or interest (including without limitation interest acquired through a license or other right to use) other than those owned by the Company or any Company Subsidiary, setting forth in each case the jurisdictions in which the Issued Patents have been issued and Patent Applications (each as included within the Aeroquin™ IP) have been filed, and the nature of the right, title or interest held by the Company or any Company Subsidiary, provided however, such list need not include Patents licensed to the Company or any Company Subsidiary under an agreement which does not specifically list the Patents being licensed.
Disclosure of Patents. Section 3.9(b)(i)(A) of the Seller Disclosure Schedules lists all of the Patents owned by or purported to be owned by Seller or any of its Affiliates and included in the Acquired Proprietary Rights (the “Acquired Patents”), setting forth in each case the jurisdictions in which Issued Patents have been issued and Patent Applications have been filed and a list of any filings or payment of fees that are due to any Governmental Authority during the ninety (90) day period following the Closing. For the avoidance of doubt, the term “Acquired Patents” means and includes (i) the Patents listed in Section 3.9(b)(i)(A) of the Seller Disclosure Schedules and all foreign counterparts of such Patents (collectively, the “Selected Patents”) and (ii) all siblings (divisional, continuation, continuation-in-part, reexaminations, revivals, utility models, registrations, extensions, and reissues) of the Selected Patents issued by, or applied for with, any Governmental Authority in any country or jurisdiction (“Additional Transferred Patents”).
Disclosure of Patents. Schedule 4.11(b)(i)(A) of the Target Disclosure Schedules lists all of the Patents owned by or purported to be owned by Target, setting forth in each case the jurisdictions in which Issued Patents have been issued and Patent Applications have been filed and a detailed description of any filings or payment of fees that, to the Knowledge of Target, are due to any Governmental Authority during the one hundred eighty (180) day period following the Closing. Schedule 4.11(b)(i)(B) of the Target Disclosure Schedules lists all of the Patents in which Target has any right, title or interest (including without limitation interest acquired through a license or other right to use), other than those owned by or purported to be owned by Target, setting forth in each case the jurisdictions in which the Issued Patents have been issued and Patent Applications have been filed (but in both such cases only where Target possesses such right, title or interest), and the nature of the right, title or interest held by Target.
Disclosure of Patents. 4.1 During the REVIEW PERIOD, as defined in Section 8.2 below, or within forty five (45) days after the EFFECTIVE DATE if a SPECIFICATION has been finally adopted by the BOARD OF DIRECTORS prior to the EFFECTIVE DATE, the LICENSING MEMBER shall disclose to the BOARD OF DIRECTORS, in writing, the existence of any NECESSARY CLAIMS of any of its patents or patent applications that are personally known to the individuals acting on behalf of the LICENSING MEMBER with respect to the SPECIFICATION and that have been determined, by the LICENSING MEMBER, to cover the SPECIFICATION. It is understood and agreed that such individuals do not represent that they personally know of all potentially pertinent claims of patents and patent applications owned or claimed by the LICENSING MEMBER or any third parties.
4.2 The obligation set forth in Section 4.1 above does not, however, imply any obligations on MEMBERS (collectively or individually) to perform or conduct patent searches. Further, nothing in this AGREEMENT nor the act of a MEMBER submitting, supporting, or approving a proposal for a SPECIFICATION shall be construed or otherwise interpreted as any kind of express or implied representation that such MEMBER does or does not hold any patents or patent applications which contain claims that cover such SPECIFICATION.
4.3 Upon adoption by the BOARD OF DIRECTORS of a SPECIFICATION, as set out in Section 8.2 or 8.3 below without timely withdrawal under Section 9.1 below, each MEMBER that has NECESSARY CLAIMS hereby covenants to grant to each of the other MEMBERS, under reasonable and nondiscriminatory terms and conditions (including a reasonable royalty rate), a nonexclusive, nontransferable, license under its NECESSARY CLAIMS, to implement that SPECIFICATION in a FULLY COMPLIANT manner, and to sell, promote or otherwise distribute the resulting implementation, which license may be made subject to the condition that those who seek licenses under this Section 4.3 agree to reciprocate or upon such other terms as the relevant parties agree, provided however, that for such grants of third parties rights which a MEMBER has the right to make, the grant shall be subject at least to the terms and conditions that the MEMBER is subject to, which terms and conditions shall be considered reasonable and nondiscriminatory. The negotiation of licenses pursuant to this Section 4.3 shall be left to the parties concerned. Additionally, in no event shall a MEMBER be required to grant a licen...
Disclosure of Patents. Section 3.10(b)(i)(A) of the Target Disclosure Schedule lists all of the Patents that constitute Target Owned Proprietary Rights, setting forth in each case the jurisdictions in which Issued Patents have been issued and Patent Applications have been filed and a description of any filings or payment of fees that are due to any Governmental Entity during the ninety (90) day period following the Closing. Section 3.10 (b)(i)(B) of the Target Disclosure Schedule lists all of the Patents in which Target or any Target Subsidiary has any ownership of any right, title or interest, other than those that constitute Target Owned Proprietary Rights.
Disclosure of Patents. APPLICATIONS TO MYOGEN. Within thirty (30) days of Myogen's request, Abbott shall provide Myogen a list of Patents and patent applications in a given Patent family. If, following Myogen's receipt of such list(s), Myogen requests additional information, Abbott shall provide to Myogen the complete text of, and all other information in its possession or control directly related to (a) all patent applications included in the given Patent family filed anywhere in the Territory; and (b) all patents included in the given Patent family as well as all information in Abbott's, its Affiliates and its patent counsel's possession concernxxx xxx institution or possible institution of any interference, opposition, reexamination, reissue, revocation, nullification or any official proceeding involving an issued patent included in the given Patent family anywhere in the Territory.
